首页> 外文期刊>Journal of the American Society of Nephrology: JASN >Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis.
【24h】

Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis.

机译:抗纤溶酶原抗体会损害纤维蛋白溶解,并与ANCA相关的血管炎中的肾脏组织学有关。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Antibodies recognizing plasminogen, a key component of the fibrinolytic system, associate with venous thrombotic events in PR3-ANCA vasculitis. Here, we investigated the prevalence and function of anti-plasminogen antibodies in independent UK and Dutch cohorts of patients with ANCA-associated vasculitis (AAV). We screened Ig isolated from patients (AAV-IgG) and healthy controls by ELISA. Eighteen of 74 (24%) UK and 10/38 (26%) Dutch patients with AAV had anti-plasminogen antibodies compared with 0/50 and 1/61 (2%) of controls. We detected anti-plasminogen antibodies in both PR3-ANCA- and MPO-ANCA-positive patients. In addition, we identified anti-tissue plasminogen activator (tPA) antibodies in 13/74 (18%) patients, and these antibodies were more common among patients with anti-plasminogen antibodies (P = 0.011). Eighteen of 74 AAV-IgG (but no control IgG) retarded fibrinolysis in vitro, and this associated with anti-plasminogen and/or anti-tPA antibody positivity. Only 4/18 AAV-IgG retarded fibrinolysis without harboring these antibodies; dual-positive samples retarded fibrinolysis to the greatest extent. Patients with anti-plasminogen antibodies had significantly higher percentages of glomeruli with fibrinoid necrosis (P < 0.05) and cellular crescents (P < 0.001) and had more severely reduced renal function than patients without these antibodies. In conclusion, anti-plasminogen and anti-tPA antibodies occur in AAV and associate with functional inhibition of fibrinolysis in vitro. Seropositivity for anti-plasminogen antibodies correlates with hallmark renal histologic lesions and reduced renal function. Conceivably, therapies that enhance fibrinolysis might benefit a subset of AAV patients.
机译:识别纤溶酶原(纤溶系统的关键组成部分)的抗体与PR3-ANCA血管炎中的静脉血栓形成有关。在这里,我们调查了抗纤溶酶原抗体在独立的英国和荷兰人群中与ANCA相关的血管炎(AAV)患者的患病率和功能。我们通过ELISA筛选了从患者(AAV-IgG)和健康对照中分离的Ig。 74名(24%)英国患者和18/30(26%)荷兰AAV患者中有18名具有抗纤溶酶原抗体,而对照组为0/50和1/61(2%)。我们在PR3-ANCA和MPO-ANCA阳性患者中均检测到抗纤溶酶原抗体。此外,我们在13/74(18%)的患者中鉴定出了抗组织纤溶酶原激活剂(tPA)抗体,这些抗体在具有抗纤溶酶原抗体的患者中更为常见(P = 0.011)。 74种AAV-IgG(但无对照IgG)中有18种在体外延迟了纤维蛋白溶解,这与抗纤溶酶原和/或抗tPA抗体阳性有关。只有4/18的AAV-IgG可以阻止纤维蛋白溶解而不携带这些抗体。双阳性样品最大程度地抑制了纤维蛋白溶解。具有抗纤溶酶原抗体的患者的肾小球百分比与纤维蛋白样坏死(P <0.05)和细胞月牙(P <0.001)相比,肾功能明显降低,而没有这些抗体的患者则更为严重。总之,抗纤溶酶原和抗tPA抗体出现在AAV中,并与体外纤维蛋白溶解的功能抑制有关。抗纤溶酶原抗体的血清阳性与肾标志性组织学病变和肾功能降低相关。可以想象,增强纤维蛋白溶解的疗法可能会使一部分AAV患者受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号